Desni Dantone
Medical · Bedford, PANPI 1861494635
Payments from drug & device makers
Across 194 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$743
- Novo Nordisk$396
- Amgen$236
- Pfizer$210
- Gilead$187
- Exact Sciences$166
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,14898%
- Education$722%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $743 |
| Novo Nordisk | 21 | $396 |
| Amgen | 13 | $236 |
| Pfizer | 14 | $210 |
| Gilead | 10 | $187 |
| Exact Sciences | 9 | $166 |
| Lilly USA, LLC | 10 | $164 |
| Abbott | 7 | $151 |
| Astellas Pharma US Inc | 5 | $149 |
| Merck | 6 | $106 |
| Xeris Pharmaceuticals, Inc. | 6 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $91 |
| GSK | 4 | $79 |
| Novartis | 5 | $72 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $65 |
| Bayer | 4 | $57 |
| Dexcom, Inc. | 3 | $53 |
| Indivior Inc. | 3 | $48 |
| Boston Scientific | 2 | $44 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Organon | 1 | $24 |
| Seqirus USA Inc | 1 | $19 |
| AstraZeneca | 1 | $15 |
| Medtronic | 1 | $13 |
| Philips North America LLC | 1 | $13 |
How this compares
$3,220 in reported general payments places this provider in the 85th percentile of 2,594 medical providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Wellbutrin XlBupropion Hcl | 13 | $33,044 |
| OzempicSemaglutide | 24 | $31,889 |
| MounjaroTirzepatide | 25 | $31,354 |
| EliquisApixaban | 47 | $30,046 |
| JardianceEmpagliflozin | 40 | $25,292 |
| FarxigaDapagliflozin Propanediol | 14 | $17,317 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $15,974 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $5,534 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,179 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $5,079 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $4,445 |
| PremproEstrogen,con/M-Progest Acet | 13 | $2,851 |
| Duloxetine Hcl | 70 | $1,606 |
| Gabapentin | 86 | $1,520 |
| Atorvastatin Calcium | 147 | $1,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Prempro | $210 | $32,89660 claims |
| Novo NordiskOzempic | $396 | $31,88924 claims |
| Lilly USA, LLCMounjaro | $164 | $31,35425 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $79 | $20,41937 claims |
| AstraZenecaFarxiga | $15 | $17,31714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,594 medical providers in Pennsylvania.
Other medical in Bedford
- Jacqueline KernaghanSpringfield$427K
- Drew SodaNew Hope$220K
- Angela KapalkoPhiladelphia$123K
- Linda PerryPhiladelphia$123K
- Cory DavidsonErie$119K
- Shelley SassamanTamaqua$90K
- Meghan HoffnerBethlehem$86K
- Thomas IacovoniDanville$72K
- Scott CoxWynnewood$66K
- Sarah SmithPhiladelphia$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.